Fabrice Bauer

Prof. Fabrice Bauer

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ABAthénaïs Boucly
Athénaïs Boucly
LSLaurent SAVALE
Laurent SAVALE
XJXavier Jaïs
Xavier Jaïs
Fabrice BauerFabrice Bauer
Fabrice Bauer
EBEmmanuel Bergot
Emmanuel Bergot
OSOlivier Sitbon
Olivier Sitbon
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods: A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results: Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions: Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.

14 September 2004 in Circulation
Verified
Journal Article
Closed access
PDF file
Fabrice BauerFabrice Bauer
Fabrice Bauer
HEHélÈnE Eltchaninoff
HélÈnE Eltchaninoff
CTChristophe Tron
Christophe Tron
PLPierre-FrançoIs Lesault
Pierre-FrançoIs Lesault
CACarla Agatiello
Carla Agatiello
ACAlain Cribier
Alain Cribier
Background— The newly developed percutaneous heart valve (PHV) implantation technique decreases transaortic pressure gradient in patients with aortic stenosis. PHV replacement effects on left ventricular (LV) global and regional systolic function are currently unknown. Methods and Results— Eight patients with severe aortic stenosis had 2D echocardiography at baseline and 24 hours after PHV implantation to evaluate changes in LV volume and LV ejection fraction. Regional function, ie, both peak systolic anterior and posterior wall tissue velocity, as well as strain and strain rate imaging, were measured by tissue Doppler imaging from a short-axis view. At 24 hours, a significant reduction in transaortic mean pressure gradient (from 46±15 to 8±3 mm Hg; P <0.0001) was accompanied by an increase in aortic valve area (from 0.59±0.11 to 1.69±0.11 cm 2 ; P <0.0001). LV end-diastolic volume remained unchanged (102±36 to 101±12 mL; P =NS), whereas LV ejection fraction increased (48±18% to 57±12%; P <0.01). Improvement in posterior wall displacement (posterior wall tissue velocity increased from 2.2±0.5 to 4.4±1.0 cm/s −1 ; P =0.0003) and deformation (strain rate imaging increased from 1.0±0.3 to 1.9±0.7 s −1 , P =0.009, and strain increased from 11±5% to 17±9%; P =0.02) were observed. Conclusions— Immediately after PHV replacement, improvement of LV global and regional systolic function was evidenced by tissue Doppler imaging.

17 June 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
JCJean-Louis Chauvet
Jean-Louis Chauvet
SEShari El-Dash
Shari El-Dash
ODOlivier Delastre
Olivier Delastre
BBBernard Bouffandeau
Bernard Bouffandeau
DJDominique Jusserand
Dominique Jusserand
MSMichel Slama
Michel Slama
Introduction: Based on previously published case reports demonstrating dynamic left intraventricular obstruction (IVO) triggered by hypovolemia or catecholamines, this study aimed to establish: (1) IVO occurrence in septic shock patients; (2) correlation between the intraventricular gradient and volume status and fluid responsiveness; and (3) mortality rate.Method: We prospectively analyzed patients with septic shock admitted to a general ICU over a 28-month period who presented Doppler signs of IVO. Clinical characteristics and hemodynamic parameters as well as echocardiographic data regarding left ventricular function, size, and calculated mass, and left ventricular outflow Doppler pattern and velocity before and after fluid infusions were recorded.Results: During the study period, 218 patients with septic shock were admitted to our ICU. IVO was observed in 47 (22 %) patients. Mortality rate at 28 days was found to be higher in patients with than in patients without IVO (55 % versus 33 %,p< 0.01). Small, hypercontractile left ventricles (end-diastolic left ventricular surface 4.7 ± 2.1 cm2/m2and ejection fraction 82 ± 12 %), and frequent pseudohypertrophy were found in these patients. A rise ≥12 % in stroke index was found in 87 % of patients with IVO, with a drop of 47 % in IVO after fluid infusion.Conclusion: Left IVO is a frequent event in septic shock patients with an important correlation with fluid responsiveness. The mortality rate was found to be higher in these patients in comparison with patients without obstruction.

14 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CFCharles Fauvel
Charles Fauvel
OROlivier Raitiere
Olivier Raitiere
ABAthénaïs Boucly
Athénaïs Boucly
PGPascal De Groote
Pascal De Groote
SRSébastien Renard
Sébastien Renard
Fabrice BauerFabrice Bauer
Fabrice Bauer

1 April 2010 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
Fabrice BauerFabrice Bauer
Fabrice Bauer
MLMathieu Lemercier
Mathieu Lemercier
AZAlan Zajarias
Alan Zajarias
CTChristophe Tron
Christophe Tron
HEHelene Eltchaninoff
Helene Eltchaninoff
ACAlain Cribier
Alain Cribier

20 July 2018 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
EBEmmanuelle Berthelot
Emmanuelle Berthelot
Fabrice BauerFabrice Bauer
Fabrice Bauer
JEJean-Christophe Eicher
Jean-Christophe Eicher
EFErwan Flécher
Erwan Flécher
BGBarnabas Gellen
Barnabas Gellen
TDThibaud Damy
Thibaud Damy
Pulmonary hypertension (PH) is a common and severe complication of heart failure (HF). Consequently, HF is the leading cause of PH. For many years, specialists have attempted to better understand the pathophysiology of PH in HF, to define its prevalence and its impact on prognosis in order to improve the therapeutic management of these patients. Nowadays, despite the recent guidelines published on the subject, several points remain unclear or debated, and until now, no study has demonstrated the efficacy of any treatment. The aim of this review is to report the evolution of the concepts on post-capillary PH (diagnosis, prevalence, prognosis, and therapeutics). The main issues are raised, focusing especially on the link between structural alterations and haemodynamic abnormalities, to discuss the possible reasons for treatment failures and future potential targets.